A Partnership to Translate an Evidence-based Intervention (Take Heart) for Vulnerable Older Adults With Heart Disease
A Partnership to Translate an Evidence-based Intervention for Vulnerable Older Adults With Heart Disease
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Michigan
-
Ann Arbor, Michigan, United States, 48104
- University of Michigan, School of Public Health
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion criteria:
50 years or older
1 or more diagnosed cardiovascular conditions, including:
- Atrial fibrillation
- Angina
- Myocardial infarction
- Congestive heart failure
- Valvular disease (aortic stenosis or mitral regurgitation)
- Peripheral vascular disease
- Pulmonary hypertension
- OR >2 major risk factors for cardiovascular disease (CVD; high cholesterol, high blood pressure, smoking, diabetes, chronic kidney disease-stage 3 or 4)
- Must have access to a mobile or landline telephone
- Must be able to travel to group sessions, with or without transportation assistance
Exclusion Criteria
• Limited fluency in English posing significant barrier to deriving program benefit
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Take Heart self-management program
Group and telephone-based educational program to enhance self-management of heart disease and related risk factors.
|
Participants receive an evidence-based heart disease self management program consisting of a combination of five two and a half hour group sessions and telephone counseling offered by a trained facilitator employed by the Detroit Area Agency on Aging.
The program is designed so that participants select an area to work on (e.g., diet, exercise, medication taking, communication with health care professionals) and receive support, information, and encouragement from group members and program facilitators, to help them reach their goals.
|
|
No Intervention: Waitlist control
Control group participants will be offered the opportunity to participate in Take Heart following the conclusion of their study involvement.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Hospitalizations
Time Frame: Baseline and 12-month follow up
|
This will be measured by asking participants to report the number of nights they have stayed overnight in the hospital during the past year, for something related to their own health.
We will ask this at baseline and then at the 12 month mark after the completion of the baseline survey, so that we can compare the year prior to the intervention to the year they completed the intervention.
In addition, when possible, we will verify self-reported hospitalizations with Electronic Medical Record (EMR) data from our partners at the Detroit Medical Center (DMC).
We will only be able to look into the EMRs of those participants that are patients at the DMC.
Change will be indicated by difference between count at baseline and count at follow-up.
|
Baseline and 12-month follow up
|
|
Emergency Department Visits
Time Frame: Baseline and 12 month follow up
|
This will be measured by asking participants to report the number of times they went to the emergency department for something related to their own health, during the past year.
We will ask this at baseline and then at the 12 month mark after the completion of the baseline survey, so that we can compare the year prior to the intervention to the year they completed the intervention.
In addition, when possible, we will verify self-reported Emergency Department visits with Electronic Medical Record (EMR) data from our partners at the Detroit Medical Center (DMC).
We will only be able to look into the EMRs of those participants that are patients at the DMC.
Change will be indicated by difference between count at baseline and count at follow-up.
|
Baseline and 12 month follow up
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Health-related Quality of Life
Time Frame: Baseline and 12-month follow-up
|
Health-related quality of life (HRQOL) was measured with the PROMIS-29 (Patient-Reported Outcomes Measurement Information System-29) profile measure, which assesses depression, anxiety, pain interference, physical function, fatigue, satisfaction with social role participation, and sleep disturbance (4 items each, 5 point Likert scales).
Higher values indicate poorer health.
One item (11 point scale) measures pain intensity on a scale of 0 -10, 0=no pain, 10=worst pain).
The T-score rescales the raw score into a standardized score with a mean of 50 and a standard deviation (SD) of 10. https://www.assessmentcenter.net/documents/PROMIS%20Profile%20Scoring%20Manual.pdf
This table indicates the mean score in each domain at the 12-month follow up time point for both intervention and control groups, as well as the difference between the means of the two groups at the 12-month time point.
|
Baseline and 12-month follow-up
|
|
Cardiac Symptom Experience
Time Frame: Baseline and 12-month follow-up
|
The cardiac symptom subscale of the Symptom and Health Problem Profile (Janz et al., 1999) asks about the frequency of chest pain/discomfort; shortness of breath; waking up from sleep because of chest pain or pressure; waking up from sleep because of shortness of breath or difficulty breathing; and irregular heartbeat or palpitations (not present, once or twice/week, a few times/week, once/day, several times/day) in the prior 12 months.
Symptom frequency (0 to 4) was summed, yielding an overall symptom burden score that ranged from 0 to 20.
Higher scores indicate worse health.
Change is indicated by the difference in mean frequency from baseline to follow-up.
|
Baseline and 12-month follow-up
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Cathleen M Connell, PhD, University of Michigan School of Public Health
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- HUM00092196
- 1R01AG047203-01A1 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.